Karyopharm Therapeutics (KPTI) Upgraded to Sell by BidaskClub

Share on StockTwits

BidaskClub upgraded shares of Karyopharm Therapeutics (NASDAQ:KPTI) from a strong sell rating to a sell rating in a research report sent to investors on Thursday, BidAskClub reports.

Other equities analysts have also issued reports about the stock. HC Wainwright reiterated a buy rating on shares of Karyopharm Therapeutics in a research report on Wednesday, February 27th. ValuEngine upgraded shares of Karyopharm Therapeutics from a sell rating to a hold rating in a research report on Wednesday, February 27th. JPMorgan Chase & Co. lowered shares of Karyopharm Therapeutics from an overweight rating to a neutral rating and dropped their price target for the stock from $21.00 to $7.00 in a research report on Friday, March 1st. Wedbush dropped their price target on shares of Karyopharm Therapeutics from $19.00 to $14.00 and set an outperform rating for the company in a research report on Monday, February 25th. Finally, Zacks Investment Research lowered shares of Karyopharm Therapeutics from a hold rating to a sell rating in a research report on Saturday, February 2nd. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the stock. The company has an average rating of Hold and an average price target of $17.75.

Shares of NASDAQ KPTI opened at $6.19 on Thursday. The company has a debt-to-equity ratio of 0.98, a current ratio of 6.19 and a quick ratio of 6.19. The company has a market cap of $371.27 million, a P/E ratio of -1.97 and a beta of 3.09. Karyopharm Therapeutics has a 12-month low of $3.92 and a 12-month high of $21.71.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its earnings results on Thursday, May 9th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.25). The business had revenue of $0.16 million for the quarter, compared to the consensus estimate of $0.75 million. Karyopharm Therapeutics had a negative net margin of 1,005.85% and a negative return on equity of 119.66%. Equities research analysts anticipate that Karyopharm Therapeutics will post -3.77 EPS for the current year.

In other news, major shareholder Ltd Chione sold 1,481,643 shares of the business’s stock in a transaction on Wednesday, February 27th. The shares were sold at an average price of $4.81, for a total value of $7,126,702.83. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 13.26% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. BlueMountain Capital Management LLC purchased a new position in shares of Karyopharm Therapeutics in the first quarter worth $233,000. Morgan Stanley lifted its holdings in shares of Karyopharm Therapeutics by 91.4% in the first quarter. Morgan Stanley now owns 164,317 shares of the company’s stock worth $960,000 after buying an additional 78,464 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Karyopharm Therapeutics by 2.7% in the first quarter. Wellington Management Group LLP now owns 8,437,359 shares of the company’s stock worth $49,275,000 after buying an additional 220,578 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Karyopharm Therapeutics by 5.1% in the first quarter. Geode Capital Management LLC now owns 586,659 shares of the company’s stock worth $3,426,000 after buying an additional 28,732 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in shares of Karyopharm Therapeutics by 115.6% in the first quarter. Renaissance Technologies LLC now owns 918,800 shares of the company’s stock worth $5,366,000 after buying an additional 492,547 shares in the last quarter. 87.72% of the stock is currently owned by hedge funds and other institutional investors.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase IIb clinical study in treatments of refractory multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for multiple myeloma patients; Phase III clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; Phase IIb clinical study in diffuse large B-cell lymphoma; Phase II/III clinical study in liposarcoma; Phase III clinical trial in endometrial cancer; and Phase II clinical trial in glioblastoma multiforme.

Featured Article: Do back-end load funds outperform no-load funds?

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Autoliv  PT Lowered to $62.00 at Buckingham Research
Autoliv PT Lowered to $62.00 at Buckingham Research
Shotspotter  Cut to “Market Perform” at Northland Securities
Shotspotter Cut to “Market Perform” at Northland Securities
Buckingham Research Increases Sonic Automotive  Price Target to $20.00
Buckingham Research Increases Sonic Automotive Price Target to $20.00
Vail Resorts  Earns Market Perform Rating from Analysts at Wells Fargo & Co
Vail Resorts Earns Market Perform Rating from Analysts at Wells Fargo & Co
Johnson Outdoors  Downgraded by Sidoti
Johnson Outdoors Downgraded by Sidoti
Autoliv  Stock Rating Upgraded by Robert W. Baird
Autoliv Stock Rating Upgraded by Robert W. Baird


© 2006-2019 Ticker Report